Bronstein, Gewirtz & Grossman, LLC: A Class Action Lawsuit Against GSK plc
On February 28, 2025, Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, announced the filing of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE:GSK) and certain of its officers. The lawsuit alleges that the defendants violated the federal securities laws during the period from February 5, 2020, to August 14, 2022.
Class Definition
The lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired GSK American Depositary Receipts (“ADRs”) during the aforementioned period, referred to as the “Class Period.”
Allegations Against GSK
The complaint alleges that GSK and its officers made false and misleading statements and/or failed to disclose material adverse facts regarding the Company’s business, operational, and financial condition, including:
- Underreporting of the financial impact of the COVID-19 pandemic on the Company’s business;
- Inadequate disclosures regarding the Company’s restructuring program;
- Failure to disclose the true state of the Company’s research and development pipeline;
- Failure to disclose the true state of the Company’s relationship with regulatory authorities;
Implications for Individual Investors
If you purchased or otherwise acquired GSK ADRs during the Class Period, you may be eligible to participate in the class action lawsuit. The lawsuit could result in monetary compensation for investors who experienced financial losses due to the alleged securities law violations.
Global Implications
The lawsuit against GSK could have far-reaching implications for the pharmaceutical industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other companies in the sector and potentially result in stricter regulations and disclosure requirements.
Conclusion
The filing of the class action lawsuit against GSK plc and certain of its officers by Bronstein, Gewirtz & Grossman, LLC, alleging securities law violations during the period from February 5, 2020, to August 14, 2022, could result in significant financial compensation for individual investors who purchased or otherwise acquired GSK ADRs during this time. Furthermore, the lawsuit could have broader implications for the pharmaceutical industry, potentially leading to increased regulatory scrutiny and disclosure requirements.
For more information about the lawsuit or if you believe you may be eligible to participate, please contact Bronstein, Gewirtz & Grossman, LLC directly.
